Last month we asked for the name of the medication, currently under review by the FDA, that has been shown to delay the development of type-1 diabetes by an average of almost three years.
CONGRATS: Diane Fry, a T1 pumper from the great state of Indiana, for being the first person with the correct answer!
ANSWER: TEBLIZUMAB. This groundbreaking drug has been used for decades to prevent the rejection of transplanted organs. Provention Bio has studied it in small doses for short time periods as a way to preserve beta cell function in people who have the antibodies that cause T1D but have not yet developed diabetes. An FDA ruling for using the medication for this purpose is expected this fall.
Type-1 University recently enrolled its 1000th student. This online “school of higher learning for insulin users” features webinar-type classes on more than a dozen different topics.
Over the past year, WHICH COURSE HAS BEEN TAKEN THE MOST?
Integrated Diabetes Services is the worldwide leader in one-on-one consulting for people who use insulin. Diabetes “coaching” services are available in-person and remotely via phone and the internet for children and adults.